Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep575 | Endocrine-Related Cancer | ECE2022

Somatostatin analogues in the treatment of metastatic paraganglioma

Roque Joao , Regala Catarina , Silva Tiago , Leite Valeriano

Introduction: Paraganglioma (PGL) is a neuroendocrine tumor derived from extra adrenal autonomic paraganglia with a germinal mutation rate of 30%. Metastatic paraganglioma (MPGL) can only be predicted after evidence of secondary lesions and it can occur in up to 50% of cases. Clinical course is remarkably variable, but 5-year overall survival is generally around 50%. Treatment options include surgical resection, chemotherapy, radiotherapy, and 123I-MIBG. Being a neu...

ea0092ps3-29-04 | Treatment 2 | ETA2023

Effectiveness of lenvatinib in progressive metastatic radioiodine refractory well differentiated and poorly differentiated thyroid carcinoma

Nunes da Silva Tiago , Regala Catarina , Rodrigues Ricardo , Roque Joao , Damasio Ines , Cavaco Branca , Leite Valeriano

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...